<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34449295</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-0970</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Multiple sclerosis (Houndmills, Basingstoke, England)</Title>
          <ISOAbbreviation>Mult Scler</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.</ArticleTitle>
        <Pagination>
          <StartPage>817</StartPage>
          <EndPage>830</EndPage>
          <MedlinePgn>817-830</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/13524585211035333</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to present primary results of a Phase 3, double-blind, ADS-5102 trial (INROADS) for walking speed.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Adult participants with MS and walking impairment, not currently using amantadine or dalfampridine, underwent 4-week placebo run-in before randomization 1:1:1 to placebo, 137 or 274 mg/day ADS-5102 for 12 weeks. Primary outcome was the proportion of responders (20% increase in Timed 25-Foot Walk (T25FW) speed) for 274 mg ADS-5102 versus placebo at end of double-blind (Study Week 16). Additional measures included Timed Up and Go (TUG), 2-Minute Walk Test (2MWT), and 12-item Multiple Sclerosis Walking Scale (MSWS-12).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 558 participants were randomized and received double-blind treatment. Significantly more participants responded with 274 mg ADS-5102 (21.1%) versus placebo (11.3%). Mean T25FW speed also significantly improved (0.19 ft/s) versus placebo (0.07 ft/s). Other measures were not significant using prespecified hierarchical testing procedure. Adverse events led to discontinuation for 3.8% (placebo), 6.4% (137 mg ADS-5102), and 20.5% (274 mg ADS-5102).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">INROADS met its primary endpoint, showing a significantly greater proportion of participants with meaningful improvement in walking speed for 274 mg ADS-5102 versus placebo. Numeric dose response was seen for some secondary efficacy outcomes and adverse events.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Jeffrey A</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0001-9245-9772</Identifier>
            <AffiliationInfo>
              <Affiliation>Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cameron</LastName>
            <ForeName>Michelle H</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Veterans Affairs Portland Health Care System/Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goldman</LastName>
            <ForeName>Myla D</ForeName>
            <Initials>MD</Initials>
            <Identifier Source="ORCID">0000-0002-5675-945X</Identifier>
            <AffiliationInfo>
              <Affiliation>Virginia Commonwealth University, Richmond, VA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goodman</LastName>
            <ForeName>Andrew D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>University of Rochester Medical Center, Rochester, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miller</LastName>
            <ForeName>Aaron E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>The Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rollins</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Llorens</LastName>
            <ForeName>Lily</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patni</LastName>
            <ForeName>Rajiv</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elfont</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Reed</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mult Scler</MedlineTA>
        <NlmUniqueID>9509185</NlmUniqueID>
        <ISSNLinking>1352-4585</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BF4C9Z1J53</RegistryNumber>
          <NameOfSubstance UI="D000547">Amantadine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2-Minute Walk Test</Keyword>
        <Keyword MajorTopicYN="N">Multiple Sclerosis Walking Scale-12</Keyword>
        <Keyword MajorTopicYN="N">Multiple sclerosis</Keyword>
        <Keyword MajorTopicYN="N">Timed 25-Foot Walk</Keyword>
        <Keyword MajorTopicYN="N">Timed Up and Go</Keyword>
        <Keyword MajorTopicYN="N">amantadine</Keyword>
        <Keyword MajorTopicYN="N">randomized controlled trial</Keyword>
      </KeywordList>
      <CoiStatement><b>Declaration of conflicting interests:</b> The author(s) declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: J.A.C. has
received personal compensation for consulting for Adamas, Atara, Bristol Myers
Squibb, Convelo, MedDay, and Mylan and for serving as an editor of
<i>Multiple Sclerosis Journal</i>. M.H.C. has received personal
compensation as a consultant for Adamas, Greenwich Biosciences, MedLink, and
Helius Medical Technologies. M.D.G. has served as a consultant for Adamas,
Biogen Idec, Brainstorm Cell Therapeutics Ltd., EMD Serono, Genentech, Greenwich
Biosciences, Immunic, MedDay, and Sanofi Genzyme; she is funded by National MS
Society Grant RG-2004-36580. A.D.G. has received consulting fees from Adamas,
Greenwich Biosciences, and SwanBio; his employer has received research support
from Biogen and Sanofi Genzyme. A.E.M. has served as a consultant for AbbVie,
Caremark, Adamas, Biogen Idec, Bristol Myers Squibb/Celgene, Corrona, EMD
Serono, Mapi-Pharma, Mylan, Novartis, and Roche/Genentech; he has received
research support from Genzyme/Sanofi, Novartis, Roche/Genentech, and MedDay, and
is on the speaker’s bureau (providing unbranded programs only) at EMD Serono
(journal club), Alexion, Biogen Idec, and Genentech (disease awareness
programs). A.R. and R.J. are employees and own stock in Adamas Pharmaceuticals,
Inc. L.L. is a former employee of, and currently receives personal compensation
as a consultant for Adamas Pharmaceuticals. R.P. and R.E. are former employees
of and own stock in Adamas Pharmaceuticals.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>17</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34449295</ArticleId>
        <ArticleId IdType="pmc">PMC8978468</ArticleId>
        <ArticleId IdType="doi">10.1177/13524585211035333</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Alonso A, Hernan MA.
Temporal trends in the incidence of multiple sclerosis: a
systematic review. Neurology
2008; 71:
129–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4109189</ArticleId>
            <ArticleId IdType="pubmed">18606967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wallin MT, Culpepper WJ, Campbell JD, et al.. The prevalence of MS in the
United States: A population-based estimate using health claims
data. Neurology
2019; 92:
e1029–e1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6442006</ArticleId>
            <ArticleId IdType="pubmed">30770430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heesen C, Bohm J, Reich C, et al.. Patient perception of bodily
functions in multiple sclerosis: Gait and visual function are the most
valuable. Mult Scler
2008; 14(7):
988–991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18505775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Feys P, Gijbels D, Romberg A, et al.. Effect of time of day on
walking capacity and self-reported fatigue in persons with multiple
sclerosis: a multi-center trial. Mult Scler
2012; 18(3):
351–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21969239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kister I, Chamot E, Salter AR, et al.. Disability in multiple
sclerosis: a reference for patients and clinicians.
Neurology
2013; 80:
1018–1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3653203</ArticleId>
            <ArticleId IdType="pubmed">23427319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Doshi A, Chataway J.
Multiple sclerosis, a treatable disease.
Clin Med
2016; 16:
s53–s59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6329568</ArticleId>
            <ArticleId IdType="pubmed">27956442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kamm CP, Uitdehaag BM, Polman CH.
Multiple sclerosis: Current knowledge and future
outlook. Eur Neurol
2014; 72(3–4):
132–141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25095894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Blight AR, Henney HR, 3rd, Cohen R.
Development of dalfampridine, a novel pharmacologic approach for
treating walking impairment in multiple sclerosis.
Ann N Y Acad Sci
2014; 1329:
33–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25154911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ampyra® (dalfampridine)
Extended release tablets [prescribing information].
Ardsley, NY: Acorda
Therapeutics, 2014, http://ampyra-hcp.com/local/files/PI.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>
European Medicines Agency. Fampyra 10 mg
prolonged-release tablets [summary of product
characteristics], 2017, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002097/WC500109956.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>
Goodman AD, Brown TR, Edwards KR, et al.. A phase 3 trial of extended
release oral dalfampridine in multiple sclerosis.
Ann Neurol
2010; 68(4):
494–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20976768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goodman AD, Brown TR, Krupp LB, et al.. Sustained-release oral
fampridine in multiple sclerosis: A randomised, double-blind, controlled
trial. Lancet
2009; 373:
732–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19249634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khazaei M, Karevan A, Taheri M, et al.. Comparison of the effects of
amantadine and ondansetron in treatment of fatigue in patients with multiple
sclerosis. Clin Transl Med
2019; 8: 20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6603072</ArticleId>
            <ArticleId IdType="pubmed">31263986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ledinek AH, Sajiko MC, Rot U.
Evaluating the effects of amantadine, modafanil and
acetyl-L-carnitine on fatigue in multiple sclerosis—Results of a pilot
randomized, blind study. Clin Neurol
Neurosurg
2013; 115:
S89–S99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24321164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kornhuber J, Bormann J, Hubers M, et al.. Effects of the
1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated
ion channel: A human postmortem brain study. Eur J
Pharmacol
1991; 206:
297–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1717296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Northover BJ.
Effect of pre-treating rat atria with potassium channel blocking
drugs on the electrical and mechanical responses to
phenylephrine. Biochem Pharmacol
1994; 47:
2163–2169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8031309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen W, Ren W, Zhai S, et al.. Striatal Kir2 K+ channel
inhibition mediates the antidyskinetic effects of
amantadine. J Clin Invest
2020; 130:
2593–2601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7190977</ArticleId>
            <ArticleId IdType="pubmed">32310223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hauser RA, Pahwa R, Wargin WA, et al.. Pharmacokinetics of ADS-5102
(amantadine) extended release capsules administered once daily at bedtime
for the treatment of dyskinesia. Clin
Pharmacokinet
2019; 58(1):
77–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6325984</ArticleId>
            <ArticleId IdType="pubmed">29777529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
GOCOVRI® (amantadine)
Extended release capsules [prescribing information].
Emeryville, CA: Adamas
Pharma, LLC, 2021, https://www.gocovrihcp.com/pdf/Gocovri_Prescribing_Information.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>
Cohen JA, Hunter SF, Brown TR, et al.. Safety and efficacy of
ADS-5102 (amantadine) extended release capsules to improve walking in
multiple sclerosis: A randomized, placebo-controlled, phase 2
trial. Mult Scler
2019; 25(4):
601–609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29368539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Motl RW, Cohen JA, Benedict R, et al.. Validity of the timed
25-Foot Walk as an ambulatory performance outcome measure for multiple
sclerosis. Mult Scler
2017; 23(5):
704–710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5405807</ArticleId>
            <ArticleId IdType="pubmed">28206828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaufman M, Moyer D, Norton J.
The significant change for the Timed 25-Foot Walk in the multiple
sclerosis functional composite. Mult Scler
2000; 6(4):
286–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10962550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sebastiao E, Sandroff BM, Learmonth YC, et al.. Validity of the Timed Up and
Go test as a measure of functional mobility in persons with multiple
sclerosis. Arch Phys Med Rehabil
2016; 97(7):
1072–1077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26944709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thompson AJ, Banwell BL, Barkhof F, et al.. Diagnosis of multiple
sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol
2018; 17:
162–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29275977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kurtzke JF.
Rating neurologic impairment in multiple sclerosis: An expanded
disability status scale (EDSS). Neurology
1983; 33(11):
1444–1452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6685237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gijbels D, Dalgas U, Romberg A, et al.. Which walking capacity tests
to use in multiple sclerosis? A multicentre study providing the basis for a
core set. Mult Scler
2012; 18(3):
364–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21952098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hobart JC, Riazi A, Lamping DL, et al.. Measuring the impact of MS
on walking ability: The 12-Item MS Walking Scale (MSWS-12).
Neurology
2003; 60:
31–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12525714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Posner K, Brown GK, Stanley B, et al.. The Columbia-Suicide
Severity Rating Scale: Initial validity and internal consistency findings
from three multisite studies with adolescents and adults.
Am J Psychiatry
2011; 168(12):
1266–1277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3893686</ArticleId>
            <ArticleId IdType="pubmed">22193671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hobart J, Blight AR, Goodman A, et al.. Timed 25-foot walk: Direct
evidence that improving 20% or greater is clinically meaningful in
MS. Neurology
2013; 80:
1509–1517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23535489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goldman MD, LaRocca NG, Rudick RA, et al.. Evaluation of multiple
sclerosis disability outcome measures using pooled clinical trial
data. Neurology
2019; 93:
e1921–e1931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6885577</ArticleId>
            <ArticleId IdType="pubmed">31641014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kragt JJ, van der Linden FA, Nielsen JM, et al.. Clinical impact of 20%
worsening on Timed 25-Foot Walk and 9-hole Peg Test in multiple
sclerosis. Mult Scler
2006; 12(5):
594–598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17086905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schwid SR, Goodman AD, McDermott MP, et al.. Quantitative functional
measures in MS: What is a reliable change?
Neurology
2002; 58:
1294–1296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11971105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goodman AD, Brown TR, Schapiro RT, et al.. A pooled analysis of two
phase 3 clinical trials of dalfampridine in patients with multiple
sclerosis. Int J MS Care
2014; 16(3):
153–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4204376</ArticleId>
            <ArticleId IdType="pubmed">25337058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coleman CI, Sobieraj DM, Marinucci LN.
Minimally important clinical difference of the Timed 25-Foot Walk
Test: Results from a randomized controlled trial in patients with multiple
sclerosis. Curr Med Res Opin
2012; 28(1):
49–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22073939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baert I, Freeman J, Smedal T, et al.. Responsiveness and
clinically meaningful improvement, according to disability level, of five
walking measures after rehabilitation in multiple sclerosis: A European
multicenter study. Neurorehabil Neural
Repair
2014; 28(7):
621–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24503204</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
